New combo aims to tackle Hard-to-Treat breast cancer

NCT ID NCT04837209

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer will receive the combination treatment. The goal is to see if the tumors shrink or stop growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.